Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
about
Adoptive immunotherapy against ovarian cancerRecognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognitionModern Technologies for Creating Synthetic Antibodies for Clinical application.Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Cytokine-induced NK-like T cells: from bench to bedside.Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Influence of murine mesenchymal stem cells on proliferation, phenotype, vitality, and cytotoxicity of murine cytokine-induced killer cells in cocultureMeasuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay.Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantationCytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognitionStrategies to achieve systemic delivery of therapeutic cells and microbes to tumors.Cytokine-induced killer cells promote antitumor immunityIn vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activityCytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells.Cell vehicle targeting strategies.Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.Targeting T cells with bispecific antibodies for cancer therapyAnti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.Cytokine induced killer cells as promising immunotherapy for solid tumors.Review of Chinese clinical trials on CIK cell treatment for malignancies.Natural killer cell lines in tumor immunotherapy.Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.Development and prospects for bispecific antibody-based therapeutics in cancer and other applications.Engineering antiphagocytic biomimetic drug carriers.A killer choice for cancer immunotherapy.Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.Cancer Immunotherapy with Cytokine-Induced Killer Cells.Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis.A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma.Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation.Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
P2860
Q26748905-D169C9B4-C4E1-4853-B2A6-A0D0401C140BQ27311035-716ECDBD-C8EE-4715-A61A-9CA38D7E1E6BQ30467308-3AD5CAE2-41A4-439E-BB57-651DE72520F0Q31157425-1167D9C8-F4F3-41BF-9D82-959938AAAA1AQ33762499-6BC45936-5FA8-405A-AC18-AC771D47B7A3Q33875615-8236E30F-0DE3-4F54-A1B2-04F4A3FC70DDQ34111201-8F9CE8E6-7533-48F1-9148-5327F82B04EFQ34596741-8EF9B13B-DDBC-4F5D-9216-F00602EB0DE8Q34635795-AFF7102C-51CB-4C2B-9E15-F1E8EBFE5B66Q35091555-41876A51-E2A9-426B-BD31-7D1C78621B8BQ35107127-A31AAFD5-6FD5-4E5B-881C-7A704FB3BE04Q35218943-69219187-4033-48A2-AF68-B9EB3BF8A0DEQ36544290-C85E1B60-FC33-44A6-A3CC-220E3E32D2A9Q36675446-B4009ED6-BDE8-4F9E-A844-A8967A53B3A0Q36741617-D84FF0F5-64FA-4DBD-A935-EDA7D9241FB1Q36868792-72E4E570-0809-4734-9076-23149C3F25C4Q36981154-B26E046B-2540-4912-AF91-42D60C3AF224Q37120169-7CDA2780-EBEA-4E73-82F9-EA44EB6F638EQ37220602-81119FF5-3D20-48BE-A4B2-F9DADF69847BQ37220742-C986F6D4-B188-4629-AC7A-50C7E5014E8DQ37220750-940BCD73-0F24-43DF-BB95-A5ECEE46F623Q37895924-162F5B63-AA62-4000-B8F9-4A935DC17BA6Q37981003-4EC7DD8C-FDC9-4510-B302-A6E940427298Q37998371-413CE8D7-DD10-48A7-856D-DD2BEB7FEF6DQ38002494-9A297F7D-880D-4CA9-B467-E1D1F08C49F8Q38090680-DB5EFA12-B514-49BD-A948-283651EF8F96Q38123856-CBAF296D-3711-4911-B8A0-BF59F7A0B5D2Q38208944-28A7D119-3F46-48B3-BA2B-565926870FB2Q38574526-5A6C1B92-AB6E-448A-927E-065C72EB7990Q38687547-CE5DF25B-0735-4E10-AAE0-80288207B1B6Q38740111-830FB01E-AFE6-4B37-8B48-682477A4197EQ39140544-FDCB6A23-BF65-421E-9271-7FA5C22FBCF7Q39149552-3E13266C-6515-46D2-8128-3FD170F0CEB7Q39266857-A96F8AA8-F07D-46F5-A999-A4EC6A34F304Q39354030-027FFDC0-69DB-4EAD-8FBC-DFA7A3E1A69BQ39356606-57F165C8-62A3-4F16-AAF5-DD000357306DQ39435767-B873C6AE-5EAD-4D0E-8DDD-EAF8467116CEQ39525496-87921AEA-1132-47C1-A914-3E16985C666FQ39679501-B3BFBDE4-FD00-400A-9D74-336392697F21Q39887296-3E79253D-0BAF-4869-B09A-8CE65DF8D509
P2860
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@ast
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@en
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@nl
type
label
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@ast
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@en
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@nl
prefLabel
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@ast
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@en
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@nl
P2093
P1476
Enhanced killing of primary ov ...... tibodies: a preclinical study.
@en
P2093
Chad A Hamilton
Jeanette Baker
John K Chan
Jonathan M Gall
Lawrence G Lum
Michael K Cheung
Mobin Karimi
Nelson N Teng
Robert S Negrin
Stephan Schulz
P304
P356
10.1158/1078-0432.CCR-05-2019
P407
P577
2006-03-01T00:00:00Z